Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458952 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase 1 study, sponsored by Molecular Insight Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00458952 is a Phase 1 study that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00458952, a Phase 1 study, has completed, sponsored by Molecular Insight Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
Interventions
- DRUG Ultratrace Iobenguane (MIBG) I 131
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458952
The ClinicalTrials.gov registry entry for NCT00458952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ultratrace Iobenguane (MIBG) I 131 is the first listed.
NCT00458952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458952 about?
NCT00458952 is a clinical study titled "Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma". The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
What is the current status of trial NCT00458952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00458952?
The interventions under investigation include: Ultratrace Iobenguane (MIBG) I 131 (DRUG).
Who is sponsoring clinical trial NCT00458952?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.